DK3137169T3 - Hæmmere af lysin-specifik demethylase-1 - Google Patents

Hæmmere af lysin-specifik demethylase-1 Download PDF

Info

Publication number: DK3137169T3
Authority: DK; Denmark
Prior art keywords: inhibitories; lysin; specific demethylase; demethylase; specific
Prior art date: 2014-05-01

Application number

DK15785884.6T

Other languages

English (en)

Inventor

Young K Chen

Toufike Kanouni

Stephen W Kaldor

Jeffrey Alan Stafford

James Marvin Veal

Original Assignee

Celgene Quanticel Res Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-01

Filing date

2015-04-30

Publication date

2022-02-14

2015-04-30 Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc

2022-02-14 Application granted granted Critical

2022-02-14 Publication of DK3137169T3 publication Critical patent/DK3137169T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polyamides (AREA)

DK15785884.6T 2014-05-01 2015-04-30 Hæmmere af lysin-specifik demethylase-1 DK3137169T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461987354P	2014-05-01	2014-05-01
PCT/US2015/028635 WO2015168466A1 (en)	2014-05-01	2015-04-30	Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number	Publication Date
DK3137169T3 true DK3137169T3 (da)	2022-02-14

Family

ID=54354743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15785884.6T DK3137169T3 (da)	2014-05-01	2015-04-30	Hæmmere af lysin-specifik demethylase-1

Country Status (31)

Country	Link
US (9)	US9255097B2 (da)
EP (1)	EP3137169B1 (da)
JP (1)	JP6493890B2 (da)
KR (1)	KR102400920B1 (da)
CN (1)	CN106659914B (da)
AR (1)	AR100251A1 (da)
AU (1)	AU2015253040B2 (da)
BR (1)	BR112016025248B1 (da)
CA (1)	CA2947283C (da)
CL (1)	CL2016002736A1 (da)
CY (1)	CY1124959T1 (da)
DK (1)	DK3137169T3 (da)
EA (1)	EA036672B8 (da)
ES (1)	ES2903423T3 (da)
HR (1)	HRP20220096T1 (da)
HU (1)	HUE057895T2 (da)
IL (1)	IL248505B (da)
LT (1)	LT3137169T (da)
MX (1)	MX2016014253A (da)
NI (1)	NI201600165A (da)
PE (1)	PE20161438A1 (da)
PH (1)	PH12016502179A1 (da)
PL (1)	PL3137169T3 (da)
PT (1)	PT3137169T (da)
RS (1)	RS62874B1 (da)
SA (2)	SA516380201B1 (da)
SG (1)	SG11201609033TA (da)
SI (1)	SI3137169T1 (da)
TW (1)	TWI676620B (da)
WO (1)	WO2015168466A1 (da)
ZA (1)	ZA201607613B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2699354T3 (es)	2014-01-17	2019-02-08	Novartis Ag	Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899491B (zh)	2014-01-17	2019-04-02	诺华股份有限公司	用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
KR102400920B1 (ko)	2014-05-01	2022-05-20	셀젠 콴티셀 리서치, 인크.	리신 특이적 데메틸라제-1의 억제제
HRP20230595T1 (hr) *	2014-07-03	2023-09-15	Celgene Quanticel Research, Inc.	Inhibitori lizina specifične demetilaze-1
KR20180011331A (ko)	2015-06-12	2018-01-31	오리존 지노믹스 에스.에이.	Lsd1 억제제와 관련된 바이오마커 및 그의 용도
US10287266B2 (en)	2015-06-19	2019-05-14	Novartis Ag	Compounds and compositions for inhibiting the activity of SHP2
JP6878316B2 (ja) *	2015-06-19	2021-05-26	ノバルティスアーゲー	Ｓｈｐ２の活性を阻害するための化合物および組成物
EP3310779B1 (en)	2015-06-19	2019-05-08	Novartis AG	Compounds and compositions for inhibiting the activity of shp2
WO2017013061A1 (en)	2015-07-17	2017-01-26	Oryzon Genomics, S.A.	Biomarkers associated with lsd1 inhibitors and uses thereof
ES2846951T3 (es) *	2015-11-05	2021-07-30	Celgene Quanticel Res Inc	Composiciones que comprenden un inhibidor de desmetilasa-1 específica para lisina, que tiene un anillo de pirimidina, y su uso en el tratamiento del cáncer
WO2017079476A1 (en)	2015-11-05	2017-05-11	Mirati Therapeutics, Inc.	Lsd1 inhibitors
AU2016360481B2 (en) *	2015-11-27	2019-09-12	Taiho Pharmaceutical Co., Ltd.	Novel biphenyl compound or salt thereof
WO2017116558A1 (en)	2015-12-29	2017-07-06	Mirati Therapeutics, Inc.	Lsd1 inhibitors
IL261721B (en)	2016-03-15	2022-07-01	Oryzon Genomics Sa	Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3430015A1 (en)	2016-03-16	2019-01-23	Oryzon Genomics, S.A.	Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
CN109415360B (zh)	2016-06-14	2021-11-02	诺华股份有限公司	用于抑制shp2活性的化合物和组合物
ES2972741T3 (es)	2016-08-10	2024-06-14	Celgene Quanticel Res Inc	Tratamiento del carcinoma de células de Merkel
JP2019532953A (ja) *	2016-09-30	2019-11-14	ノバルティスアーゲー	増強された有効性を有する免疫エフェクター細胞治療
US20190256930A1 (en)	2016-11-03	2019-08-22	Oryzon Genomics, S.A.	Biomarkers for determining responsiveness to lsd1 inhibitors
EP3535414A1 (en)	2016-11-03	2019-09-11	Oryzon Genomics, S.A.	Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018130928A1 (en)	2017-01-10	2018-07-19	Novartis Ag	Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
EP3600301B1 (en)	2017-03-30	2024-07-03	Albert-Ludwigs-Universität Freiburg	Kdm4 inhibitors
WO2018216795A1 (ja) *	2017-05-26	2018-11-29	大鵬薬品工業株式会社	新規なビフェニル化合物を用いた抗腫瘍効果増強剤
MA50466A (fr)	2017-05-26	2020-09-02	Taiho Pharmaceutical Co Ltd	Nouveau composé de biphényle ou sel de celui-ci
MA50518A (fr)	2017-05-31	2020-09-09	Taiho Pharmaceutical Co Ltd	Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
EP3661510B1 (en)	2017-08-03	2024-10-09	Oryzon Genomics, S.A.	Methods of treating behavior alterations
WO2019182960A1 (en) *	2018-03-21	2019-09-26	Synblia Therapeutics, Inc.	Shp2 inhibitors and uses thereof
CN109668987A (zh) *	2019-02-27	2019-04-23	浙江华贝药业有限责任公司	一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
SG11202109159VA (en)	2019-03-20	2021-10-28	Oryzon Genomics Sa	Methods of treating borderline personality disorder
US20220151999A1 (en)	2019-03-20	2022-05-19	Oryzon Genomics, S.A.	Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
MX2021015992A (es)	2019-06-20	2022-04-06	Celgene Quanticel Res Inc	Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
JP2022546908A (ja)	2019-07-05	2022-11-10	オリゾン・ゲノミクス・ソシエダッド・アノニマ	Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
EP4038054A1 (en) *	2019-10-01	2022-08-10	Bayer Aktiengesellschaft	Pyrimidinedione derivatives
EP4114398A1 (en) *	2020-03-06	2023-01-11	Celgene Quanticel Research, Inc.	Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
EP4161507A1 (en)	2020-06-05	2023-04-12	Celgene Quanticel Research, Inc.	Methods of treating prostate cancer
US20240216357A1 (en) *	2021-03-24	2024-07-04	Sichuan Huiyu Pharmaceutical Co., Ltd.	Polycyclic compound and application thereof
BR112023020554A2 (pt)	2021-04-08	2023-12-05	Oryzon Genomics Sa	Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides
WO2023217758A1 (en)	2022-05-09	2023-11-16	Oryzon Genomics, S.A.	Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en)	2022-05-09	2023-11-16	Oryzon Genomics, S.A.	Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en)	2022-11-24	2024-05-30	Oryzon Genomics, S.A.	Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024119067A1 (en)	2022-12-02	2024-06-06	Neumora Therapeutics, Inc.	Methods of treating neurological disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5550147A (en) *	1992-02-05	1996-08-27	Fujisawa Pharmaceutical Co., Ltd.	Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
EP1087963B1 (en) *	1998-06-19	2004-08-25	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
WO2002102313A2 (en) *	2001-06-19	2002-12-27	Bristol-Myers Squibb Company	Pyrimidine inhibitors of phosphodiesterase (pde) 7
PT2316831E (pt)	2002-11-21	2013-06-06	Novartis Ag	2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
US7183287B2 (en) *	2003-04-03	2007-02-27	Pharmacia Corporation	Substituted pyrimidinones
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
US8466163B2 (en)	2006-12-11	2013-06-18	Bionomics Limited	Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
US8916548B2 (en) *	2008-07-29	2014-12-23	Boehringer Ingelheim International Gmbh	5-alkynyl-pyrimidines
TWI435874B (zh) *	2008-10-31	2014-05-01	Toray Industries	環己烷衍生物及其醫藥用途
WO2011143057A1 (en) *	2010-05-11	2011-11-17	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
US9527805B2 (en)	2010-09-10	2016-12-27	Robert A. Casero	Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
AU2012236868B2 (en)	2011-03-25	2015-09-17	Glaxosmithkline Intellectual Property Development Limited	Cyclopropylamines as LSD1 inhibitors
WO2013175789A1 (ja)	2012-05-24	2013-11-28	出光興産株式会社	有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
US8980879B2 (en)	2013-03-11	2015-03-17	Abbvie Inc.	Bromodomain inhibitors
WO2015018522A1 (en)	2013-08-06	2015-02-12	Oncoethix Sa	Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
TWI771630B (zh)	2013-10-18	2022-07-21	美商賽基昆堤塞爾研發公司	溴結構域(bromodomain)抑制劑
HUE061252T2 (hu) *	2013-12-11	2023-05-28	Celgene Quanticel Res Inc	Lizinspecifikus demetiláz-1 inhibítorok
KR102400920B1 (ko) *	2014-05-01	2022-05-20	셀젠 콴티셀 리서치, 인크.	리신 특이적 데메틸라제-1의 억제제
WO2016014859A1 (en)	2014-07-25	2016-01-28	Pharmacyclics Llc	Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CA2966452A1 (en)	2014-12-17	2016-06-23	Samuel David Brown	Substituted bicyclic compounds as bromodomain inhibitors
ES2846951T3 (es) *	2015-11-05	2021-07-30	Celgene Quanticel Res Inc	Composiciones que comprenden un inhibidor de desmetilasa-1 específica para lisina, que tiene un anillo de pirimidina, y su uso en el tratamiento del cáncer

2015
- 2015-04-30 KR KR1020167033658A patent/KR102400920B1/ko active IP Right Grant
- 2015-04-30 EA EA201692079A patent/EA036672B8/ru not_active IP Right Cessation
- 2015-04-30 TW TW104114015A patent/TWI676620B/zh active
- 2015-04-30 SI SI201531769T patent/SI3137169T1/sl unknown
- 2015-04-30 AR ARP150101317A patent/AR100251A1/es unknown
- 2015-04-30 MX MX2016014253A patent/MX2016014253A/es active IP Right Grant
- 2015-04-30 EP EP15785884.6A patent/EP3137169B1/en active Active
- 2015-04-30 WO PCT/US2015/028635 patent/WO2015168466A1/en active Application Filing
- 2015-04-30 HR HRP20220096TT patent/HRP20220096T1/hr unknown
- 2015-04-30 PE PE2016002162A patent/PE20161438A1/es unknown
- 2015-04-30 CN CN201580035484.6A patent/CN106659914B/zh active Active
- 2015-04-30 PL PL15785884T patent/PL3137169T3/pl unknown
- 2015-04-30 RS RS20220059A patent/RS62874B1/sr unknown
- 2015-04-30 US US14/701,304 patent/US9255097B2/en active Active
- 2015-04-30 SG SG11201609033TA patent/SG11201609033TA/en unknown
- 2015-04-30 LT LTEPPCT/US2015/028635T patent/LT3137169T/lt unknown
- 2015-04-30 ES ES15785884T patent/ES2903423T3/es active Active
- 2015-04-30 CA CA2947283A patent/CA2947283C/en active Active
- 2015-04-30 BR BR112016025248-9A patent/BR112016025248B1/pt active IP Right Grant
- 2015-04-30 JP JP2016565219A patent/JP6493890B2/ja active Active
- 2015-04-30 DK DK15785884.6T patent/DK3137169T3/da active
- 2015-04-30 HU HUE15785884A patent/HUE057895T2/hu unknown
- 2015-04-30 PT PT157858846T patent/PT3137169T/pt unknown
- 2015-04-30 AU AU2015253040A patent/AU2015253040B2/en active Active
2016
- 2016-01-05 US US14/988,022 patent/US9573930B2/en active Active
- 2016-02-08 US US15/018,814 patent/US9771329B2/en active Active
- 2016-10-26 IL IL248505A patent/IL248505B/en active IP Right Grant
- 2016-10-27 CL CL2016002736A patent/CL2016002736A1/es unknown
- 2016-10-31 SA SA516380201A patent/SA516380201B1/ar unknown
- 2016-10-31 SA SA519410025A patent/SA519410025B1/ar unknown
- 2016-11-01 NI NI201600165A patent/NI201600165A/es unknown
- 2016-11-02 PH PH12016502179A patent/PH12016502179A1/en unknown
- 2016-11-04 ZA ZA2016/07613A patent/ZA201607613B/en unknown
2017
- 2017-01-09 US US15/401,894 patent/US9776974B2/en active Active
- 2017-08-23 US US15/684,886 patent/US10207999B2/en active Active
- 2017-08-25 US US15/687,251 patent/US10023543B2/en active Active
2018
- 2018-06-13 US US16/007,937 patent/US10654810B2/en active Active
2020
- 2020-04-06 US US16/841,595 patent/US11084793B2/en active Active
2021
- 2021-06-23 US US17/356,389 patent/US11987560B2/en active Active
2022
- 2022-02-01 CY CY20221100083T patent/CY1124959T1/el unknown

Also Published As

Publication number	Publication date
JP6493890B2 (ja)	2019-04-03
WO2015168466A1 (en)	2015-11-05
CA2947283A1 (en)	2015-11-05
US20170349555A1 (en)	2017-12-07
EP3137169A4 (en)	2018-01-10
US20150315187A1 (en)	2015-11-05
KR102400920B1 (ko)	2022-05-20
MX2016014253A (es)	2017-02-08
TWI676620B (zh)	2019-11-11
BR112016025248B1 (pt)	2022-12-13
CY1124959T1 (el)	2023-01-05
IL248505B (en)	2021-01-31
EP3137169B1 (en)	2021-11-10
SI3137169T1 (sl)	2022-04-29
US9776974B2 (en)	2017-10-03
IL248505A0 (en)	2016-12-29
NI201600165A (es)	2017-03-13
US10207999B2 (en)	2019-02-19
SA516380201B1 (ar)	2019-11-20
US20160152595A1 (en)	2016-06-02
EA036672B8 (ru)	2021-01-13
KR20160144506A (ko)	2016-12-16
PL3137169T3 (pl)	2022-02-28
US9573930B2 (en)	2017-02-21
EA201692079A1 (ru)	2017-04-28
AR100251A1 (es)	2016-09-21
CA2947283C (en)	2023-01-24
CN106659914A (zh)	2017-05-10
US20180325900A1 (en)	2018-11-15
RS62874B1 (sr)	2022-02-28
US10654810B2 (en)	2020-05-19
PH12016502179A1 (en)	2017-02-13
JP2017514830A (ja)	2017-06-08
US20160130247A1 (en)	2016-05-12
CL2016002736A1 (es)	2017-06-23
SG11201609033TA (en)	2016-11-29
SA519410025B1 (ar)	2022-06-01
US20200231549A1 (en)	2020-07-23
NZ725914A (en)	2023-09-29
US20170349556A1 (en)	2017-12-07
AU2015253040A8 (en)	2017-06-15
US20220153706A1 (en)	2022-05-19
US9771329B2 (en)	2017-09-26
US11084793B2 (en)	2021-08-10
EP3137169A1 (en)	2017-03-08
HRP20220096T1 (hr)	2022-04-15
US9255097B2 (en)	2016-02-09
AU2015253040B2 (en)	2020-04-09
TW201623254A (zh)	2016-07-01
US20170114024A1 (en)	2017-04-27
LT3137169T (lt)	2022-04-11
PT3137169T (pt)	2022-01-25
HUE057895T2 (hu)	2022-06-28
WO2015168466A8 (en)	2016-11-24
PE20161438A1 (es)	2017-01-18
BR112016025248A2 (pt)	2018-06-19
US10023543B2 (en)	2018-07-17
CN106659914B (zh)	2020-06-19
EA036672B1 (ru)	2020-12-07
ES2903423T3 (es)	2022-04-01
ZA201607613B (en)	2017-11-29
AU2015253040A1 (en)	2016-11-24
US11987560B2 (en)	2024-05-21

Publication	Publication Date	Title
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3134530T3 (da)	2019-09-09	Behandling af hyperbilirubinæmi
DK3102576T3 (da)	2019-07-22	Dihydropyrrolopyridininhibitorer af ror-gamma
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3180331T3 (da)	2022-09-12	Polymorfer af selinexor
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3164380T3 (da)	2022-03-28	Hæmmere af lysinspecifik demethylase-1
DK3160956T3 (da)	2020-08-31	Inhibitorer af lysin-specifik demethylase-1
DK3006072T3 (da)	2021-10-25	Karadgang
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
DK3514109T3 (da)	2021-05-25	Hydropyrolyse af biomasseholdige råmaterialer
DK3132009T3 (da)	2023-02-06	Fremgangsmåde
DK3283210T3 (da)	2021-11-22	Fremgangsmåde
DK3220891T3 (da)	2019-11-04	Sublingual formulering af riluzol
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3511000T3 (da)	2022-05-30	Krystallinsk form x2 af grapiprant
DK3368044T3 (da)	2021-09-13	Behandling af hepatisk steatose-relateret oligo-ovulation
DK3204352T3 (da)	2020-09-28	Hæmmere af lysin-gingipain
DK3201323T3 (da)	2020-02-03	Modificering af bakteriofag
DK3137449T3 (da)	2020-03-02	Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
FR3024647B1 (fr)	2017-02-17	Transat de puericulture
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement